Table 2.
Hyperhomocysteinaemia and MTHFR polymorphism distributions according to CAD, and HHcy distribution according to MTHFR polymorphism and CAD. P1 is an MTHFR polymorphism and HHcy comparison (chi-square test) and Hcy comparison (ANOVA and median tests) between cases and controls. P2 is the significant value of the hypothesis testing that the OR of CAD associated to MTHFR polymorphism and HHcy is 1. P3 is a tHcy comparison between genotypes in cases and controls separately (Kruskal-Wallis test). P4 is a tHcy comparison between genotypes in total population (Kruskal-Wallis test).
Total population | Control | Case | P1 | OR (95% CI) | P2 | |
Number of subjects | 400 | 190 | 210 | — | — | — |
MTHFR C677T | — | — | — | — | — | — |
Genotype, n (%) | — | — | — | 0.038 | — | — |
677CC | 214 (53.5) | 113 (59.5) | 101 (48.1) | — | 1.00 | — |
677CT | 139 (34.8) | 61 (32.1) | 78 (37.1) | — | 1.43 (0.93–2.20) | 0.102 |
677TT | 47 (11.8) | 16 (8.4) | 31 (14.8) | — | 2.17 (1.12–4.20) | 0.022 |
Allele, n (%) | — | — | — | 0.006 | — | — |
677C | 567 (70.9) | 287 (75.5) | 280 (66.7) | — | 1.00 | — |
677T | 233 (29.1) | 93 (24.5) | 140 (33.3) | — | 1.54 (1.11–1.84) | 0.007 |
tHcy, μmol/L | — | — | — | — | — | — |
Mean ± SD | 13.1 ± 3.6 | 11.3 ± 3.1 | 14.8 ± 3.1 | 0.000 | — | — |
Median | 13.8 | 11.1 | 14.9 | 0.000 | — | — |
HHcy, n (%) | — | — | — | 0.000 | — | — |
No | 256 (64.0) | 150 (78.9) | 106 (50.5) | — | 1.00 | — |
Yes | 144 (36.0) | 40 (21.1) | 104 (49.5) | — | 3.68 (2.37–5.72) | 0.000 |
MTHFR polymorphism | ||||||
Total population | 677CC | 677CT | 677TT | P3 | P4 | |
Number of subjects | 400 | 214 | 139 | 47 | — | — |
tHcy, μmol/L | — | — | — | — | — | 0.000 |
Case | 14.9 ± 3.1 | 13.7 ± 2.3 | 15.0 ± 2.4 | 18.3 ± 4.0 | 0.000 | — |
Control | 11.3 ± 3.1 | 10.5 ± 3.0 | 11.9 ± 2.9 | 14.1 ± 2.2 | 0.000 | — |
HHcy, n (%) | — | — | — | — | — | 0.007 |
Case | 104 (26.0) | 35 (16.4) | 42 (30.2) | 27 (57.4) | 0.000 | — |
Control | 40 (10.0) | 18 (8.4) | 14 (10.1) | 8 (17.0) | 0.007 | — |